InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Dyne Therapeutics, Inc.

DYN Clue Score44
United States Fiscal year ends December CIK 0001818794
$16.64 +1.65% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $16.64 +16.45% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 17 Sep 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2019Operating income−13.8Net income−14.9Fiscal year 2020Operating income−58.6Net income−59.4Fiscal year 2021Operating income−150.0Net income−149.3EPS, diluted−2.93Fiscal year 2022Operating income−171.0Net income−168.1EPS, diluted−3.23Fiscal year 2023Operating income−242.2Net income−235.9EPS, diluted−3.95Fiscal year 2024Operating income−343.9Net income−317.4EPS, diluted−3.37Fiscal year 2025Operating income−468.2Net income−446.2EPS, diluted−3.47
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −13.8 −58.6 −150.0 −171.0 −242.2 −343.9 −468.2
Net income −14.9 −59.4 −149.3 −168.1 −235.9 −317.4 −446.2
Growth
EPS, diluted n/a n/a −2.93 −3.23 −3.95 −3.37 −3.47
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Operating cash flow−11.8Capital expenditure−1.6Free cash flow−13.5Fiscal year 2020Operating cash flow−46.5Capital expenditure−1.2Free cash flow−47.7Fiscal year 2021Operating cash flow−119.6Capital expenditure−3.6Free cash flow−123.2Fiscal year 2022Operating cash flow−153.6Capital expenditure−3.1Free cash flow−156.7Fiscal year 2023Operating cash flow−188.2Capital expenditure−0.7Free cash flow−188.9Fiscal year 2024Operating cash flow−292.4Capital expenditure−2.4Free cash flow−294.7Fiscal year 2025Operating cash flow−403.2Capital expenditure−1.9Free cash flow−405.1
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −11.8 −46.5 −119.6 −153.6 −188.2 −292.4 −403.2
Capital expenditure −1.6 −1.2 −3.6 −3.1 −0.7 −2.4 −1.9
Free cash flow −13.5 −47.7 −123.2 −156.7 −188.9 −294.7 −405.1
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2019Cash14.6Shareholders’ equity14.0Fiscal year 2020Cash300.9Shareholders’ equity342.4Fiscal year 2021Cash200.8Shareholders’ equity368.2Fiscal year 2022Cash172.1Shareholders’ equity252.4Fiscal year 2023Cash121.6Shareholders’ equity91.3Fiscal year 2024Cash435.4Total debt0.0Net cash (debt)435.4Shareholders’ equity629.8Debt to equity0.00Fiscal year 2025Cash893.4Total debt148.9Net cash (debt)744.4Shareholders’ equity972.1Debt to equity0.15
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 14.6 300.9 200.8 172.1 121.6 435.4 893.4
Total debt n/a n/a n/a n/a n/a 0.0 148.9
Net cash (debt) n/a n/a n/a n/a n/a 435.4 744.4
Shareholders’ equity 14.0 342.4 368.2 252.4 91.3 629.8 972.1
Debt to equity n/a n/a n/a n/a n/a 0.00 0.15

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
11.0 45.2 121.3 142.8 210.8 281.4 398.3
2.8 13.4 28.7 28.2 31.4 62.5 69.9
−13.8 −58.6 −150.0 −171.0 −242.2 −343.9 −468.2
Growth
n/a n/a n/a n/a 0.0 0.0 0.0
−14.9 −59.4 −149.3 −168.1 −235.9 −317.4 −446.2
Growth
Per share
n/a n/a −2.93 −3.23 −3.95 −3.37 −3.47
n/a n/a −2.93 −3.23 −3.95 −3.37 −3.47
Growth

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 7 of 7 years on file.